Business
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinical trial in 2H 2026 WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced the presentation of new preclinical data fro
About this update from Prelude Therapeutics Incorporated
[{"type":"image","alt":"Prelude Therapeutics, Incorporated","displaySize":"","headline":null,"caption":"Prelude Therapeutics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MO954UhiNgAAy2HkWxQ5FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NA--/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555","width":300,"height":103}},"lazy":false},{"type":"text","content":"Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer ","length":176,"tagName":"p"},{"type":"text","content":"Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinical trial in 2H 2026","length":129,"tagName":"p"},{"type":"text","content":"WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced the presentation of new preclinical data from its lead development candidate, PRT13722. PRT13722 is being developed for the treatment of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2-) breast cancer (BC). Based on preclinical data, we believe PRT13722 is a highly differentiated, first-in-class, orally bioavailable, potent and highly-selective KAT6A degrader.","length":542,"tagName":"p"},{"type":"text","content":"“These preclinical data further strengthen our hypothesis that developing a highly selective degrader specifically targeting KAT6A has the potential for further improvements of efficacy and importantly an improved hematological safety profile. We believe the efficacy and safety profile of PRT13722 will, in turn, enable meaningful combination approaches to existing standards of care,” stated Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude. “We remain on track to file an Investigational New Drug (IND) application for PRT13722 in the middle of this year and, pending clearance, enter the clinic in the second half of 2026.”","length":636,"tagName":"p"},{"type":"text","content":"“There remains a significant unmet need for new treatment options to further improve the standard of care...